Literature DB >> 1984869

Mechanisms of angiotensin II- and arginine vasopressin-induced increases in protein synthesis and content in cultured rat aortic smooth muscle cells. Evidence for selective increases in smooth muscle isoactin expression.

M B Turla1, M M Thompson, M H Corjay, G K Owens.   

Abstract

Previous studies from this laboratory have demonstrated that angiotensin II (Ang II) and arginine vasopressin (AVP) are potent hypertrophic agents in cultured rat aortic smooth muscle cells. The present study identified major proteins that accumulate in Ang II-induced and AVP-induced hypertrophic cells and initiated studies of the mechanisms that contribute to their accumulation. Smooth muscle cell hypertrophy induced by Ang II and/or AVP (1 microM each) was associated with widespread increases in the content of many cellular proteins that were resolved by one- and two-dimensional gel electrophoresis. However, increases were also selective in nature, with increases in certain individual proteins, including actin (twofold to threefold), vimentin (2.5-fold to sevenfold), tropomyosin (threefold to sixfold), and myosin heavy chain, far exceeding overall increases in cellular protein content (20-40%). Increases in actin content were due largely to increased expression of smooth muscle alpha-actin (3.6- to 7.5-fold), as opposed to nonmuscle beta-actin (1.7- to 2.5-fold). Increases in smooth muscle alpha-actin were accompanied by a fivefold to eightfold increases in smooth muscle alpha-actin mRNA, indicating that these changes were not due exclusively to translational controls. Results demonstrate that contractile agonist-induced hypertrophy in cultured smooth muscle cells is due, in part, to increased expression of smooth muscle contractile proteins. Furthermore, the fact that Ang II and AVP induced selective increases in smooth muscle alpha-actin suggests that these agonists may not only regulate growth of vascular smooth muscle but may also promote expression of smooth muscle-specific contractile proteins during differentiation of vascular smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984869     DOI: 10.1161/01.res.68.1.288

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  15 in total

Review 1.  Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.

Authors:  Jeffrey A Beamish; Ping He; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Tissue Eng Part B Rev       Date:  2010-10       Impact factor: 6.389

Review 2.  Molecular biology of angiotensin receptors and their role in human cardiovascular disease.

Authors:  V Regitz-Zagrosek; M Neuss; J Holzmeister; C Warnecke; E Fleck
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

3.  Suppression of smooth-muscle alpha-actin expression by platelet-derived growth factor in vascular smooth-muscle cells involves Ras and cytosolic phospholipase A2.

Authors:  X Li; V Van Putten; F Zarinetchi; M E Nicks; S Thaler; L E Heasley; R A Nemenoff
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

4.  Angiotensin induces the urinary peristaltic machinery during the perinatal period.

Authors:  Y Miyazaki; S Tsuchida; H Nishimura; J C Pope; R C Harris; J M McKanna; T Inagami; B L Hogan; A Fogo; I Ichikawa
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

5.  Effect of the Na+/H+ antiport inhibitor Hoe 694 on the angiotensin II-induced vascular smooth muscle cell growth.

Authors:  A Sachinidis; C Seul; Y Ko; R Düsing; H Vetter
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

6.  A Novel Systems-Biology Algorithm for the Analysis of Coordinated Protein Responses Using Quantitative Proteomics.

Authors:  Fernando García-Marqués; Marco Trevisan-Herraz; Sara Martínez-Martínez; Emilio Camafeita; Inmaculada Jorge; Juan Antonio Lopez; Nerea Méndez-Barbero; Simón Méndez-Ferrer; Miguel Angel Del Pozo; Borja Ibáñez; Vicente Andrés; Francisco Sánchez-Madrid; Juan Miguel Redondo; Elena Bonzon-Kulichenko; Jesús Vázquez
Journal:  Mol Cell Proteomics       Date:  2016-02-18       Impact factor: 5.911

Review 7.  [The renin-angiotensin system in cardiovascular diseases].

Authors:  C Unterberg; H Kreuzer; A B Buchwald
Journal:  Med Klin (Munich)       Date:  1998-07-15

8.  Angiotensin II, from vasoconstrictor to growth factor: a paradigm shift.

Authors:  Sasa Vukelic; Kathy K Griendling
Journal:  Circ Res       Date:  2014-02-28       Impact factor: 17.367

9.  Angiotensin converting enzyme binding sites in human heart and lung: comparison with rat tissues.

Authors:  T Vago; M Bevilacqua; F Conci; G Baldi; E Ongini; E Chebat; A Monopoli; G Norbiato
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

Review 10.  Peripheral factors in the management of congestive heart failure.

Authors:  L Demopoulos; T H LeJemtel
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.